Health Condition 1: L501- Idiopathic urticaria
Conditions
Interventions
Intervention1: Bilastine: Participants will receive Bilastine 20 mg tablet,
administered orally once daily, 1 hour before or 2 hours after meals, for a total duration
of 42 days.
Control Intervention1
Sponsors
Dr Rajendra Prasad Government Medical College
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients willing to give informed consent. 2.Consenting adults of either sex between 18-65 years of age with documented history of chronic spontaneous urticaria, without any known inducible factor or definite cause. 3.Currently not on any prophylactic medication in last month. 4.Patients ability to fill a Urticaria activity score. diagnosed with CSU( symptoms for more than or equal to 6 weeks.
Exclusion criteria
Exclusion criteria: Dermatoses including dermographism Physical urticaria Hereditary angioedema, Food and/or drug allergy, Contact urticaria, Collagen vascular diseases, Atopic dermatitis, Systemic autoimmune disorders, Hodgkin s disease, Patients who had taken systemic or topical corticosteroids within 4 weeks, or any other oral antihistamine within 72 hours of randomization visit, Any known cause of urticaria like respiratory/ gastrointestinal infections or parasitic infestation were also excluded, Pregnant or lactating women, Known hypersensitivity to Bilastine or desloratadine, Autoimmune thyroid disorder
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| NIlTimepoint: NIL | — |
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy of Bilastine 20 mg versus Desloratadine 5 mg in reducing disease activity, measured by the change in Urticaria Activity Score over 7 days (UAS7) from baseline to Day 42 in patients with chronic spontaneous urticaria.Timepoint: Day 0 - baseline day 14 - first followup day 28 - second followup day 42 - third followup/end of treatment | — |
Countries
India
Contacts
Public ContactDr Yiesh Gathania
Dr. Rajendera Prasad Government Medical college
Outcome results
None listed